ABIVAX Société Anonyme (ABVX.PA)
EUR 7.48
(2.89%)
EUR 7.48
(2.89%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 131.05 Million EUR | 83.37% |
| 2022 | 71.47 Million EUR | -12.4% |
| 2021 | 81.59 Million EUR | 22.46% |
| 2020 | 66.62 Million EUR | 66.78% |
| 2019 | 39.94 Million EUR | 105.98% |
| 2018 | 19.39 Million EUR | 244.17% |
| 2017 | 5.63 Million EUR | 45.23% |
| 2016 | 3.88 Million EUR | -14.35% |
| 2015 | 4.53 Million EUR | 12.38% |
| 2014 | 4.03 Million EUR | -9.29% |
| 2013 | 4.44 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 158.02 Million EUR | 0.0% |
| 2023 Q2 | 90.59 Million EUR | 0.0% |
| 2023 FY | 131.05 Million EUR | 83.37% |
| 2023 Q4 | 131.05 Million EUR | 0.0% |
| 2022 Q4 | 71.47 Million EUR | 0.0% |
| 2022 Q2 | 72.39 Million EUR | 0.0% |
| 2022 FY | 71.47 Million EUR | -12.4% |
| 2021 FY | 81.59 Million EUR | 22.46% |
| 2021 Q4 | 81.59 Million EUR | 0.0% |
| 2021 Q2 | 59.56 Million EUR | 0.0% |
| 2020 Q4 | 66.62 Million EUR | 0.0% |
| 2020 Q2 | 53.4 Million EUR | 0.0% |
| 2020 FY | 66.62 Million EUR | 66.78% |
| 2019 FY | 39.94 Million EUR | 105.98% |
| 2019 Q2 | 39.62 Million EUR | 0.0% |
| 2019 Q4 | 39.94 Million EUR | 0.0% |
| 2018 Q2 | 4.95 Million EUR | 0.0% |
| 2018 FY | 19.39 Million EUR | 244.17% |
| 2018 Q4 | 19.39 Million EUR | 0.0% |
| 2017 Q2 | 4.01 Million EUR | 0.0% |
| 2017 FY | 5.63 Million EUR | 45.23% |
| 2017 Q4 | 5.63 Million EUR | 0.0% |
| 2016 Q4 | 3.88 Million EUR | 0.0% |
| 2016 Q2 | 3.79 Million EUR | 0.0% |
| 2016 FY | 3.88 Million EUR | -14.35% |
| 2015 Q2 | 8.82 Million EUR | 0.0% |
| 2015 Q4 | 4.53 Million EUR | 0.0% |
| 2015 FY | 4.53 Million EUR | 12.38% |
| 2014 Q3 | 4030.00 EUR | 0.0% |
| 2014 FY | 4.03 Million EUR | -9.29% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q4 | 4.03 Million EUR | 99924.57% |
| 2013 FY | 4.44 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -1796.007% |
| Adocia SA | 31.87 Million EUR | -311.208% |
| Aelis Farma SA | 13.08 Million EUR | -901.927% |
| Biophytis S.A. | 15.84 Million EUR | -726.879% |
| Advicenne S.A. | 24.37 Million EUR | -437.605% |
| genOway Société anonyme | 14.45 Million EUR | -806.338% |
| IntegraGen SA | 5.97 Million EUR | -2091.579% |
| Medesis Pharma S.A. | 6.42 Million EUR | -1939.344% |
| Neovacs S.A. | 3.71 Million EUR | -3430.378% |
| NFL Biosciences SA | 3.62 Million EUR | -3519.538% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -1832.25% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -3859.147% |
| Sensorion SA | 13.22 Million EUR | -890.771% |
| Theranexus Société Anonyme | 5.01 Million EUR | -2512.581% |
| TME Pharma N.V. | 2.78 Million EUR | -4605.637% |
| Valbiotis SA | 13.7 Million EUR | -856.026% |
| TheraVet SA | 1.48 Million EUR | -8725.092% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -540.278% |
| argenx SE | 402.79 Million EUR | 67.465% |
| BioSenic S.A. | 32.26 Million EUR | -306.186% |
| Celyad Oncology SA | 9.97 Million EUR | -1213.409% |
| DBV Technologies S.A. | 38.74 Million USD | -238.24% |
| Galapagos NV | 1.56 Billion EUR | 91.609% |
| Genfit S.A. | 105.92 Million EUR | -23.726% |
| GeNeuro SA | 20.13 Million EUR | -550.708% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -1421.737% |
| Innate Pharma S.A. | 132.29 Million EUR | 0.937% |
| Inventiva S.A. | 101.59 Million EUR | -28.997% |
| MaaT Pharma SA | 22.46 Million EUR | -483.361% |
| MedinCell S.A. | 77.77 Million EUR | -68.512% |
| Nanobiotix S.A. | 95.74 Million EUR | -36.883% |
| Onward Medical N.V. | 25.69 Million EUR | -409.97% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -421.59% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | -121.825% |
| Oxurion NV | 19.73 Million EUR | -564.025% |
| Pharming Group N.V. | 228.28 Million EUR | 42.593% |
| Poxel S.A. | 53.9 Million EUR | -143.135% |
| GenSight Biologics S.A. | 34.72 Million EUR | -277.378% |
| Transgene SA | 26.51 Million EUR | -394.219% |
| Financière de Tubize SA | 123.65 Million EUR | -5.986% |
| UCB SA | 6.56 Billion EUR | 98.003% |
| Valneva SE | 341.14 Million EUR | 61.585% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -2782.164% |